| Mar 2 |
Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society’s 2021 Annual Meeting
|
| Feb 17 |
Spruce Biosciences to Participate in Upcoming Investor Conferences
|
| Jan 12 |
What Type Of Shareholders Make Up Spruce Biosciences, Inc.'s (NASDAQ:SPRB) Share Registry?
|
| Jan 6 |
Spruce Biosciences outlines milestones for 2021
|
| Jan 6 |
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
|
| Dec 17 |
Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes
|
| Nov 18 |
Spruce Biosciences EPS misses by $6.26
|
| Nov 18 |
Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
|
| Nov 17 |
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
|
| Nov 4 |
Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
|
| Nov 3 |
Benzinga's Top Upgrades, Downgrades For November 3, 2020
|
| Nov 1 |
The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings
|
| Oct 19 |
Novo Holdings reports 21.5% stake in Spruce Biosciences
|
| Oct 16 |
Airbus Is Struggling. And a Contract to Build a Mars Spacecraft Can’t Lift the Earthbound Gloom.
|
| Oct 15 |
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
|
| Oct 9 |
Spruce Biosciences prices upsized IPO at $15, raising $90M
|
| Oct 6 |
Spruce Biosciences Proposes $75 Million IPO Terms
|
| Oct 5 |
Spruce Biosciences sets IPO terms
|
